Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older.
Expert Opin Pharmacother
; 11(9): 1559-67, 2010 Jun.
Article
em En
| MEDLINE
| ID: mdl-20482305
ABSTRACT
IMPORTANCE OF THE FIELD Allergic rhinitis is an IgE-mediated condition that produces inflammation of the mucosa of the nose, paranasal sinuses and, frequently, of the ocular conjunctiva. Allergic rhinitis causes a significant disease burden in terms of quality of life, lost productivity and medical treatment costs. One of the newest treatments approved by the FDA is Patanase (olopatadine hydrochloride) Nasal Spray, 665 microg/spray (OLO). Olopatadine is an antihistamine with selective H(1)-receptor antagonist activity. AREAS COVERED IN THIS REVIEW This review details the basic and clinical research on the olopatadine molecule and OLO nasal spray from 1996 to the present day. WHAT THE READER WILL GAIN The reader will gain a better understanding of the pharmacology of OLO nasal spray, the clinical trial data that have established the efficacy of OLO nasal spray and the overall role of OLO nasal spray in the management of allergic rhinitis. TAKE HOME MESSAGE Olopatadine nasal spray is one of the newest treatments approved by the FDA for the management of allergic rhinitis. OLO has a rapid onset of action, efficacy comparable to intranasal steroid sprays and is approved for seasonal allergic rhinitis in patients aged > or = 6 years.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Rinite Alérgica Sazonal
/
Antagonistas não Sedativos dos Receptores H1 da Histamina
/
Dibenzoxepinas
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Child
/
Humans
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article